Track the evolution of major financial and economic events
On April 7, Ecopetrol's board ousted CEO Ricardo Roa following allegations of influence peddling and campaign finance violations. Juan Carlos Hurtado, the current COO, will serve as interim CEO until June 28. The investigations are linked to Gustavo Petro's 2022 presidential campaign.
AstraZeneca achieved positive Phase 3 trial results for its drug Imfinzi in treating liver cancer. The drug is expected to become a 'super-blockbuster' and a major growth driver for the company. The treatment targets cases where tumors cannot be surgically removed, a category with historically limited options.
On April 7, U.S. lawmakers proposed a law that would impose new export restrictions on semiconductors to China. These restrictions specifically target ASML's deep ultraviolet (DUV) lithography machines. Following the announcement of these legislative proposals, ASML shares fell.
Citigroup is expected to report Q1 2026 earnings on April 14, with an EPS forecast of $2.60, while analysts anticipate JPMorgan Chase to post an EPS of $5.50 and revenue of $48.30 billion on the same day. Both banks maintain a 'Moderate Buy' rating despite recent insider selling reports. Meanwhile, Simply Good Foods is set to release its Q2 earnings on April 9, with an EPS expectation of $0.40, down from last year's figures.
Sanofi reported positive phase 2 results for Lunsekimig in asthma and nasal polyps. The AIRCULES phase 2b study met its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status. The DUET phase 2a study also met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps. However, the exploratory VELVET phase 2b study did not meet its primary endpoint in moderate-to-severe atopic dermatitis.
On April 7, Blue Owl Capital's stock price dropped to $8.45, a significant decline from its all-time high of $25. This sharp decline has erased billions of dollars in market value for the company. The decline is linked to growing concerns regarding the stability of the private credit industry.
Samsung forecasts more than an eightfold increase in first-quarter operating profit. This growth is primarily driven by the semiconductor business and strong demand for AI-related chips.
The private credit sector is facing mixed redemption pressures, with Blue Owl (OWL) shares plummeting 68.2% from their peak due to redemptions totaling $5.4 billion. Goldman Sachs' private credit fund received redemption requests for just under 5% of shares in Q1, remaining below its quarterly cap. This surge in redemptions reflects liquidity strains and investor anxiety across the broader private credit sector.
On April 6, the Trump administration announced a 2.48% increase in Medicare Advantage payments for 2027. This final rate is significantly higher than the proposed 0.09% increase in January. The total increase is estimated to be worth over $13 billion for health insurers.
Vizsla Silver confirmed the death of nine of its employees in a tragic incident in Concordia, Sinaloa. The incident occurred on April 6, causing significant shock and sorrow in the local community and within the company.
Verizon announced a plan to return approximately $55 billion to shareholders through dividends and share repurchases by the end of 2028. The company also completed its acquisition of Frontier, expanding fiber access to over 30 million homes and businesses. Daniel Schulman has been appointed as the new CEO, and Mark Bertolini as the independent Chair.
On April 6, Ascendis Pharma launched YUVIWEL, the first once-weekly treatment for children with achondroplasia in the U.S. The treatment received orphan drug exclusivity until February 27, 2033. The company has already begun revenue recognition following approval and initiation of therapy for the first patients.
PSEG is leveraging its nuclear assets to meet the surging power demand from AI data centers. The company reported a non-GAAP EPS of $4.05 for 2025 with an 18% revenue growth. Additionally, the 2026 guidance targets an EPS of $4.28 to $4.40, supported by a $25 billion capital expenditure plan.
Global Payments has unveiled a $600 million synergy plan alongside ambitious growth targets for 2026. The company aims for 13-15% adjusted EPS growth by 2026. Additionally, it plans a $7.5 billion capital return by 2027, which includes $2.5 billion in share repurchases. Expected expense synergies of $600 million are anticipated from the Worldpay acquisition.
On April 6, Insulet Corporation announced a recall of specific lots of Omnipod 5 Pods in the U.S. due to a manufacturing defect causing internal insulin leakage. 18 serious adverse events have been reported, including hospitalizations and diabetic ketoacidosis, with no fatalities. The manufacturing defect results in under-delivery of insulin to users.
StubHub shares plummeted 35% in March following a disappointing earnings report. The company's second earnings report showed revenue declines and missed analyst expectations. Challenges included a lack of major events like Taylor Swift tours and the industry's shift to 'all-in' ticket pricing.
On April 6, Transocean added $1 billion to its backlog through new offshore drilling contracts. The contracts are located in geographical regions including Norway and Brazil. These contracts strengthen the company's long-term visibility in the ultra-deepwater drilling sector.
Alphabet's capital expenditure is projected to reach between $175 billion and $185 billion by 2026. Google Cloud maintains a backlog of $240 billion, justifying aggressive infrastructure investments. Vertical integration through custom TPUs enables significant cost savings and margin improvements in AI delivery.
The retreat of the US Dollar provided relief to global stocks during a calm trading session. As the Tuesday deadline for a US-Iran deal loomed, volatility remained high after Iran rejected peace terms. Market participants are awaiting US CPI data on Friday to assess the risk of imminent rate hikes. Following Iran's rejection of a ceasefire plan, WTI crude prices surged, putting pressure on stocks. With the ceasefire officially in effect, ecstatic flows into markets were observed.
Lucid Motors is facing a survival crisis due to stagnating sales growth, which is a vital metric for the survival of EV companies. On April 13, Lucid Group's stock price was $8.58, near its 52-week low of $8.56.
SBA Communications (SBAC) shares surged 18.9% in the last session with higher-than-average trading volume. Recent trends in Funds From Operations (FFO) estimate revisions indicate potential for further price increases in the near term.
On April 6, McCormick & Company amended its 8-K report to provide definitive details on its planned $15.7 billion acquisition of Unilever's foods business. The deal uses a Reverse Morris Trust structure, resulting in Unilever shareholders holding 55.1% to 65% of McCormick's common stock. The company also secured a $15.7 billion bridge facility to finance the transaction.
On April 6, Opus Genetics signed a strategic financing agreement with Oberland Capital worth up to $155 million. The financing includes a $35 million upfront payment and a $5 million equity investment, extending the company's cash runway into 2029. Funds will be used to accelerate gene therapy programs for inherited retinal diseases and support upcoming clinical trials.
On April 6, Playtika's Board of Directors formed a Special Committee of independent directors to conduct a comprehensive review of strategic alternatives. The review aims to enhance and unlock shareholder value across the company's portfolio. Morgan Stanley & Co. LLC has been retained as the financial advisor for the process.
